Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026)
Canopy Growth (CGC) posted Total Non-Current Liabilities of $279.8 million for Q1 2026, up 12.13% sequentially from $249.6 million in Q4 2025, and little changed YoY from $280.8 million in Q1 2025.
Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth has reported Total Non-Current Liabilities for 10 years, with the latest figure at $279.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed 0.33% year-over-year to $279.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $279.8 million (changed 0.33% YoY) and the FY2026 annual result came in at $279.8 million, changed 0.33% from the prior year.
- Total Non-Current Liabilities climbed to $279.8 million in Q1 2026 per CGC's latest filing, from $249.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.5 billion in Q1 2022 and troughed at $242.6 million in Q3 2025.
- A 5-year average of $726.7 million and a median of $598.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities sank 54.31% in 2025, then decreased 0.33% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $1.1 billion in 2022, then tumbled by 47.26% to $598.7 million in 2023, then sank by 31.52% to $410.0 million in 2024, then plunged by 39.13% to $249.6 million in 2025, then increased by 12.13% to $279.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $279.8 million, $249.6 million, and $242.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | 279.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 279.08 Mn |
| Mar 31, 2026 | 279.84 Mn |
| Dec 31, 2025 | 249.56 Mn |
| Sep 30, 2025 | 242.57 Mn |
| Jun 30, 2025 | 300.01 Mn |
| Mar 31, 2025 | 280.76 Mn |
| Dec 31, 2024 | 410.00 Mn |
| Sep 30, 2024 | 529.76 Mn |
| Jun 30, 2024 | 550.77 Mn |
| Mar 31, 2024 | 614.43 Mn |
| Dec 31, 2023 | 598.71 Mn |
| Sep 30, 2023 | 685.33 Mn |
| Jun 30, 2023 | 926.46 Mn |
| Mar 31, 2023 | 1.24 Bn |
| Dec 31, 2022 | 1.14 Bn |
| Sep 30, 2022 | 1.34 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.51 Bn |
| Sep 30, 2021 | 1.64 Bn |